INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Observational study / 2012

In women operated on for early breast cancer, serum enterolactone levels ≥ 10 nmol/l were linked to reduced all-cause and breast cancer-specific mortality.

Researchers measured serum enterolactone levels in 300 patients operated on for early breast cancer to evaluate mortality risk over a median follow-up of 23 years (range 0.6-26.1). During follow-up, 180 patients died, including 112 from breast cancer-related events. Enterolactone levels ≥ 10 nmol/l were significantly associated with lower risks of both all-cause and breast cancer-specific mortality. The difference in mortality hazards appeared to decrease and lose significance after the first 10 years, though competing risk analysis indicated breast cancer-related mortality risk remained constantly lower in patients with higher enterolactone levels.

Shows an association, not proof of cause and effect.

Study type
Retrospective cohort study
Who was studied
300 women operated on for early breast cancer
What was measured
All-cause mortality and breast cancer-specific mortality

THE PAPER

Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study.

Guglielmini P, Rubagotti A, Boccardo F. Breast Cancer Res Treat, 2012.

PubMed 22094938 ↗DOI 10.1007/s10549-011-1881-8 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.